Combination of PDT and topical angiogenic inhibitor for treatment of port wine stain (PWS) birthmarks - A novel approach

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 7380, Issue , 2009, Pages

  Yuan, Kaihua ^a   Huang, Qiaobing ^b   Huang, Zheng ^c  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

angiogenic inhibitor; PDT; photothermolysis; Port Wine Stains; VEGF

Indexed keywords

ANGIOGENIC INHIBITOR; PDT; PHOTOTHERMOLYSIS; PORT WINE STAINS; VEGF;

DYE LASERS; LASER SURGERY; PLASMONS; WINE;

PHOTODYNAMIC THERAPY;

EID: 70449658261     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.823280     Document Type: Conference Paper

References (27)

1. Ritter MR, R.A. Butschek, M. Friedlander, Pathogenesis of infantile haemangioma: new molecular and cellular insights. Expert Rev Mol Med. 2007;9:1-19. (Pubitemid 351695558)
2. Orten SS, Waner M, Flock S. Port wine stains: an assessment of 5 years of treatment. Arch Otolaryngol Head Neck Surg. 1996;122:1174-1179.
3. Michel S, Landthaler M, Hohenleutner U. Recurrence of port-wine stains after treatment with the flashlamp-pumped pulsed dye laser. Br J Dermatol. 2000;143:1230-1234. (Pubitemid 32052760)
4. Huikeshoven M, Koster PH, de Borgie CA, Beek JF, van Gemert MJ, van der Horst CM. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med. 2007;356:1235-40. (Pubitemid 46465599)
5. Phung TL, Oble DA, Jia W, Benjamin LE, Mihm MC Jr, Nelson JS. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks. Laser Surg Med. 2008;40:1-5. (Pubitemid 351214117)
6. Chang CJ, Hsiao YC, Mihm MC Jr, Nelson JS. Pilot study examining the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks. Laser Surg Med. 2008;40:605-610.
7. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000;60:4066-9. (Pubitemid 30636586)
8. Qiang YG, Yow CM, Huang Z. Combination of photodynamic therapy and immunomodulation: current status and future trends. Med Res Rev. 2008 Jul;28(4):632-44. (Pubitemid 351842144)
9. Frimpong-Boateng A, Bunse A, Rüfer F, Roider J. Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients. Acta Ophthalmol. 2009;87:183-7.
10. Alster TS, Railan D. Laser treatment of vascular birthmarks. J Craniofac Surg. 2006;17:720-723. (Pubitemid 44174600)
11. Kelly KM, Choi B, McFarlane S, et al. Description and analysis of treatments for port-wine stain birthmarks. Arch Facial Plast Surg. 2005;7:287-294. (Pubitemid 43973810)
12. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat. 2005;4:283-93. (Pubitemid 40807688)
13. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214.
14. Huang Z. Photodynamic therapy in China: 25 years of unique history - Part two: Clinical experience. Photodiag Photodyn Ther. 2006a;3:71-84. (Pubitemid 43795948)
15. Huang Z. Photodynamic therapy in China: 25 years of unique history - Part one: History and domestic photosensitizers. Photodiag Photodyn Ther. 2006b;3:3-10.
16. Huang NY. What is the optimal PDT protocol for treating port wine stains (PWS)? Photodiag Photodyn Ther. 2007;4:145-146.
17. Yuan KH, Li Q, Yu WL, Zeng D, Zhang C, Huang Z. Comparison of photodynamic therapy and pulsed dye laser in patients with port wine stain birthmarks: a retrospective analysis. Photodiagn Photodyn Ther. 2008;5:50-7.
18. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-158. (Pubitemid 37045363)
19. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100:3767-3775. (Pubitemid 35303950)
20. Kouba DJ, Yip D, Fincher EF, Moy RL. Topical imiquimod in the treatment of a long-standing capillary malformation. Br J Dermatol. 2007;157:1071-1072. (Pubitemid 47583528)
21. Ho NT, Lansang P, Pope E. Topical iniquimod in the treatment of infantile hemangiomas: A retrospective study. J Am Acad Dermatol. 2007;56:63-68. (Pubitemid 46016997)
22. Barry RB, Hughes BR, Cook LJ, Involution of infantile haemangiomas after imiquimod 5% cream. Clin Exp Dermatol. 2008;33:446-449. (Pubitemid 351832123)
23. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43:S6-S11. (Pubitemid 30447906)
24. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-347. (Pubitemid 38333711)
25. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304. (Pubitemid 40202568)
26. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185. (Pubitemid 46829388)
27. Weyergang A, Berg K, Kaalhus O, Peng Q, Selbo PK. Photodynamic therapy targets the mTOR signaling network in vitro and in vivo. Mol Pharm. 2009;6:255-64.